- Home
- Publications
- Publication Search
- Publication Details
Title
Second line treatment of acromegaly: Pasireotide or Pegvisomant?
Authors
Keywords
-
Journal
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
Volume -, Issue -, Pages 101684
Publisher
Elsevier BV
Online
2022-07-17
DOI
10.1016/j.beem.2022.101684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
- (2021) Przemysław Witek et al. Frontiers in Endocrinology
- Pasireotide in the Personalized Treatment of Acromegaly
- (2021) Manel Puig-Domingo et al. Frontiers in Endocrinology
- Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST2 in Mediating Ligand Effects
- (2021) Jessica Amarù et al. Cancers
- Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation
- (2021) Maria Stelmachowska-Banaś et al. Pituitary
- The Future of Somatostatin Receptor Ligands in Acromegaly
- (2021) Monica R Gadelha et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Somatostatin Analogs in Clinical Practice: a Review
- (2020) Mariana Gomes-Porras et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide
- (2020) Soraya Puglisi et al. Frontiers in Endocrinology
- Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
- (2020) Annamaria Colao et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response
- (2020) Sabrina Chiloiro et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
- (2019) Adrian Daly et al. Endocrine Connections
- Pegvisomant improves Glucose Metabolism in Acromegaly: a meta-analysis of prospective interventional studies
- (2019) Tiziana Feola et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study
- (2019) Sabrina Chiloiro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Pegvisomant and Pasireotide LAR on vertebral fractures in acromegaly resistant to First-Generation SRLs
- (2019) Sabrina Chiloiro et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
- (2018) Christian J Strasburger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly
- (2018) Sabrina Chiloiro et al. Pituitary
- Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
- (2018) Francesco Ferraù et al. Frontiers in Endocrinology
- Systemic complications of acromegaly and the impact of the current treatment landscape: an update
- (2018) Mônica R Gadelha et al. ENDOCRINE REVIEWS
- Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study
- (2018) Ammar Muhammad et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY
- (2018) Michael Buchfelder et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression
- (2018) Ammar Muhammad et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
- (2017) Eva Venegas-Moreno et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas
- (2017) Federico Gatto et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- AIP and the somatostatin system in pituitary tumours
- (2017) Alejandro Ibáñez-Costa et al. JOURNAL OF ENDOCRINOLOGY
- Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
- (2017) Felipe F. Casanueva et al. Pituitary
- The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis
- (2016) Sanne E. Franck et al. NEUROENDOCRINOLOGY
- Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant
- (2016) Sanne E. Franck et al. NEUROENDOCRINOLOGY
- Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY
- (2015) Philippe Chanson et al. ANNALES D ENDOCRINOLOGIE
- Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey
- (2015) C. Schofl et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
- (2015) Donato Iacovazzo et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- A Structural and Functional Acromegaly Classification
- (2015) Daniel Cuevas-Ramos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential somatostatin receptor (SSTR) 1–5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors
- (2015) Katja Kiseljak-Vassiliades et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Acromegaly: Assessing the Disorder and Navigating Therapeutic Options for Treatment
- (2014) Shlomo Melmed et al. Endocrine Practice
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
- (2014) A. Colao et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The exon 3-deleted growth hormone receptor: Molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions
- (2014) M. Filopanti et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
- (2014) A. Giustina et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
- (2014) Mônica R Gadelha et al. Lancet Diabetes & Endocrinology
- Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern
- (2013) Leandro Kasuki et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide
- (2013) Olivera Casar-Borota et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY
- (2012) A. J. van der Lely et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly
- (2011) Stine Lyngvi Fougner et al. CLINICAL ENDOCRINOLOGY
- Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly
- (2011) Ansgar Heck et al. CLINICAL ENDOCRINOLOGY
- Resistance to Somatostatin Analogs in Acromegaly
- (2011) Annamaria Colao et al. ENDOCRINE REVIEWS
- Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers
- (2011) Stephan Petersenn et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model
- (2010) Beatrice Waser et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pituitary somatostatin receptor signaling
- (2010) Anat Ben-Shlomo et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Pituitary-independent effect of octreotide on IGF1 generation
- (2009) Ana Pokrajac et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pegvisomant Improves Insulin Sensitivity and Reduces Overnight Free Fatty Acid Concentrations in Patients with Acromegaly
- (2009) C. E. Higham et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The clinical–molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology
- (2009) Diego Ferone et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Somatostatin analog and pegvisomant combination therapy for acromegaly
- (2009) Sebastian J. C. Neggers et al. Nature Reviews Endocrinology
- A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
- (2008) I M Holdaway et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Prognostic Significance of the Ki-67 Labeling Index in Growth Hormone-Secreting Pituitary Adenomas
- (2008) A. Fusco et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly
- (2008) Antonio Bianchi et al. Pituitary
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search